EVIDENS: Lung Cancer Patients Treated With Nivolumab: A Longitudinal, Prospective, Observational, Multicentric Study
Latest Information Update: 15 Dec 2023
At a glance
- Drugs Nivolumab (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- Acronyms EVIDENS
- Sponsors Bristol-Myers Squibb
- 24 Oct 2023 Results from NCT03382496 and NCT02910999, describing RW survival outcomes of patients with aNSCLC who resumed nivo after interrupting an initial nivo treatment received as 2+ line-of-therapy presented at the 48th European Society for Medical Oncology Congress
- 21 Sep 2021 Results assessing long-term overall survival (OS) and health-related quality of life (HRQoL)., presented at the 46th European Society for Medical Oncology Congress.
- 01 Jul 2021 Results of pooled analysis of a real world patients (n=2585)from EVIDENS and ENLARGE and a retrospective registry study evaluating Two-year survival with nivolumab in previously treated advanced non small-cell lung cancer published in the Lung Cancer